Arvinas climbs on positive data from breast cancer treatment trial

Arvinas

16/05/2024 17:37

** Shares of drug developer Arvinas  ARVN.O  rise ~3.5% to
$33.44 
    ** Co says updated data from early-stage trial shows that
ARVN's vepdegestrant in combination with Pfizer's  PFE.N 
Ibrance continued to show positive results in patients with a
form of breast cancer  
    ** Patients achieved a median progression-free survival of
13.9 months at the recommended dose during trial
    ** ARVN says data is consistent with data presented at the
San Antonio Breast Cancer Symposium in December 2023
    ** Including session's move, stock down 18.6% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))